Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK112 + paclitaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- Kangfang Sainuo Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
AK112 + paclitaxel + carboplatin is an experimental three-drug combination regimen evaluated primarily for advanced non-small cell lung cancer (NSCLC). AK112 is a first-in-class, humanized IgG1 bispecific antibody targeting both programmed death-1 (PD-1) and vascular endothelial growth factor (VEGF), designed to enhance antitumor immunity and inhibit angiogenesis. Paclitaxel is a microtubule-stabilizing chemotherapeutic agent, and carboplatin is a platinum-based DNA-damaging agent. In phase II clinical trials, this combination has demonstrated promising efficacy as first-line treatment for advanced NSCLC without driver mutation, as well as for patients with EGFR mutations refractory to EGFR-TKI therapies. AK112 is developed by Akeso Biopharma, with trials funded jointly with the National Natural Science Foundation of China.
- Brand names
- Idafang
- Other names
- ivonescimab, AK-112, SMT-112ivonescimabAK-112AK112AK 112SMT-112SMT112SMT 112
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)DNA
Beyond the preview
Go deeper on AK112 + paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK112 + paclitaxel + carboplatin.